Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 3, 2015Journal of Hematology & OncologyOpen Access

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJingjing WuZunyi Medical UniversityJFJiaping FuShaoxing People's HospitalMZMingzhi ZhangMinistry of Education

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wu et al. (2015) studied this question.

synapsesocial.com/papers/69e1bc76aba40719165f6ab0https://doi.org/10.1186/s13045-015-0195-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies2014 · 32 citations
  2. 2Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia2014 · 24 citations
  3. 3Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class2007 · 190 citations
  4. 4How I treat acute lymphocytic leukemia in adults2007 · 36 citations